

Robert Harriss
Texas A&M University,
College Station, TX 77843-3136, USA
E-mail: harriss@tamu.edu

4650 Wismer Road,
Doylestown, PA 18901, USA

Clean Air Skepticism

Polio Vaccine Production

In the debate between Alan W. Dove and Vincent R. Racaniello (Policy Forum, 8 Aug., p. 779) and Harry F. Hull and R. Bruce Aylward (Policy Forum, 8 Aug., p. 780) about whether or not to convert polio vaccination from oral to inactivated vaccine during the last stages of eradication, the supply of enhanced-potency inactivated vaccine is an important consideration. Currently, Pasteur Mérieux Connaught supplies most of the inactivated polio vaccine (IPV) used in the world. In our opinion, expanded production to 500 million doses per year would be feasible if enough advance notice were given, particularly in view of the likelihood that other manufacturers would enter into production of IPV.

Stanley A. Plotkin
Emeritus Professor of Pediatrics,
University of Pennsylvania, and
Consultant, Pasteur Mérieux Connaught,

The article by Jocelyn Kaiser about the debate over tightened ambient air quality standards (News & Comment, 25 July, p. 466) does a good job of presenting the U.S. Environmental Protection Agency's (EPA's) side of the story, but does not mention several of the scientific issues that make up the basis for widespread skepticism. Most of the new epidemiological studies have examined short-term (daily) responses, including mortality. However, because of temporal colinearity among pollutants and uncertain exposures of the putative victims, it is not possible to apportion blame among potential environmental agents with certainty (1, 2). The effects of carbon monoxide have often been neglected, and the effect of particle size (if any) remains unclear (3). As Kaiser points out, there are also questions about the degree of prematurity of death.

Two recent mortality studies considered long-term survival rates of defined cohorts in relation to the average air pollution con-

centrations, as measured during periods of follow-up. Kaiser describes the first of these studies (4) as "convincing"; it reported that about 26% of all deaths in six U.S. cities were attributable to air pollution, thus putting air pollution on a par with smoking and implying that eliminating air pollution could have about the same health benefit as eliminating all human cancers, for example. Kaiser quotes me as allowing that a systematic gradient in lifestyle across the six cities "might" account for the mortality gradient that was attributed to air pollution. Such a regional gradient in physical activity exists (5), and its implied effect on longevity is almost exactly the same as that shown in an independent study of individuals in California (6). Accounting for this confounding variable would leave a mortality excess of only about 5% (in the most polluted city), and this excess could well be a result of the much higher historic exposures that were present in that city (6). My concern is thus much more than a hypothetical "what if."

Studies that conclude that current air pollution is as lethal as smoking or cancer have omitted known confounders such as diet, physical exercise, income, and employment status, and treat nonlinear factors (for example, body mass and education) as if they were linear. The second cohort study

Have you ever received inferior results after performing manual fragment or mutation analysis? Did you know inferior results can often be traced directly to the gel? It's true. Although they're commonly used, all agarose gels offer limited resolution—especially when compared to acrylamide gels. Great DNA fragment and mutation analysis results begin and end with acrylamide gel technology.


Acrylamide gel technology: for the best results

Reliable, high resolution acrylamide gel technology can now give you great results in SSCP, VNTR, DDRT, RAPD, and other applications. From capture to staining, you can now use a complete system of products that are designed to work together. What's more, all are based on acrylamide gel technology. The system comprises: GenePhor electrophoresis unit, a range of acrylamide gels called GeneGels, a power supply, the Hoefer Automated Gel Stainer, and the Silver Staining Kit.

Used together, or individually, the system delivers many benefits. Like precise temperature control from 5.0 to 65.0°C, the reliability and reproducibility of pre-cast acrylamide gels and buffer strips, automated silver staining of the utmost in reproducibility. All of which, you'll find, save you time and provide you with convenience. Thanks to its new electrode holder, buffer strip holder, and temperature control, GenePhor gives you high reproducibility and unmatched convenience in an electrophoresis unit. Pre-cast GeneGels offer the type of high reproducibility and resolution levels that are extremely difficult to achieve in producing your own acrylamide gels. The Hoefer Automated Gel Stainer automatically handles the time and attention dictated by silver staining.

Only Pharmacia Biotech offers a complete system based on acrylamide gel technology. Find out more. Give us a call: 1 (800) 526-3593 in the USA; +81 3492 6949 in Japan; +46 18 16 50 11 in Europe and the rest of the world.

Or look for the products within our homepage: <http://www.biotech.pharmacia.se>.



RAPD analysis of bacterial strains. Lanes 1 and 19, 100 ng 100 Base Pair Ladder; lane 2, no DNA control reaction; lanes 3-14, *E. coli* DNAs; lane 15, *K. pneumoniae* DNA; lane 16, *S. typhimurium* DNA; lane 17, *E. aerogenes* DNA; lane 18, *C. freundii* DNA.



Uppsala, Sweden. (And the rest of the world)

Circle No. 43 on Readers' Service Card

(7) also suffered from most of these design faults, and it considered only two pollutants, neglecting the influence of their correlates. These two studies (4, 7) are thus a shaky basis on which to attempt to interpret the ambiguous daily studies.

Finally, the scientific skepticism about this issue runs much deeper than just pro forma industrial opposition. A recent invited critical review of the particulate matter standards expressed doubt about the validity of both the short- and long-term mortality studies (8), and other academics have expressed similar opinions (9, 10). EPA would be well advised to demonstrate the actual public health benefits already accrued from its existing air quality regulations before mandating the hefty additional investments that meeting the new regulations will require.

Frederick W. Lipfert
Environmental Consultant,
23 Carll Court,
Northport, NY 11768, USA

References

1. J. M. Samet, S. L. Zeger, J. E. Kelsall, J. Xu, "Air pollution, weather, and mortality in Philadelphia, 1973-88, Report to the Health Effects Institute on Phase 1B: Particle Epidemiology Evaluation Project" (Johns Hopkins Univ. Press, Baltimore, MD, 1996).
2. R. T. Burnett, S. Cakmak, J. R. Brook, D. Krewski, *Environ. Health Perspect.* **105**, 614 (1997).
3. F. W. Lipfert and R. E. Wyzga, *J. Air Waste Manag. Assoc.* **47**, 517 (1997).
4. D. W. Dockery et al., *N. Engl. J. Med.* **329**, 1753 (1993).
5. E. L. Frazier, C. A. Okoro, C. Smith, D. V. McQueen, *Morbid. Mortal. Wkly. Rep.* **45** (no.556), 1 (1996).
6. F. W. Lipfert, in *Particulate Matter: Health and Regulatory Issues* (Air and Waste Management Association, Publ. VIP 49, Proceedings of the International Specialty Conference, Pittsburgh, PA, April 1995), pp. 78-102.
7. C. A. Pope, III, M. J. Thun, M. M. Namboodiri, D. W. Dockery, J. S. Evans, *Am. J. Resp. Crit. Care Med.* **151**, 669 (1995).
8. S. Vedal, *J. Air Waste Manag. Assoc.* **47**, 551 (1997).
9. R. F. Phalen, testimony before subcommittees on health and environment and on oversight and investigations, Committee on Commerce, U.S. House of Representatives, 8 May 1997.
10. A. A. Moghissi, *Environ. Intl.* **23**, 147 (1997).



Genetic Evolution of Morphology

Two commentaries in the 4 July issue, by their contrast, inadvertently point to a missing element in most discussions of the evolution of animal form. In his Perspective "Which came first, the hypha or the yeast?" (p. 52), P. T. Magee draws the lesson from a report by B. R. Braun and A. D. Johnson (4 July, p. 105) that the existence of a simple genetic switch between the budding yeast and the thread-like hypha morpholo-

gies of *Candida albicans* suggests that "there is no 'default' form for this organism." This seems reasonable: *C. albicans* is thought of as polymorphic, with numerous forms being consistent with a single genetic constitution. The choice between alternative forms in such cases may depend on epigenetic or environmental factors, although, in principle, heritable genetic change could bias such choices, leading to distinct morphological varieties.

This view may be compared with one presented in the Special News Report by Elizabeth Pennisi and Wade Roush "Developing a new view of evolution" (4 July, p. 34), in which they discuss, among other things, recently published evidence that a gene called *manx* distinguishes a species of tunicates whose larvae lack tails from a related species whose larvae develop them (B. J. Swalla and W. R. Jeffery, Reports, 15 Nov., 1996 p. 1205). We are told in the News article that the result "raises the possibility that a single genetic change could be responsible for the innovation that led to a tail in primitive vertebrates."

The attribution of ineffable creative power to individual genes is not an isolated instance, but can be traced back at least to the erroneous "unit character" model of Mendelism propounded by some early ge-

FELIX

CALL FOR PROPOSALS

CLIO

for research in (bio)physics, (bio)chemistry or (bio)medicine

by two Infrared Free Electron Laser facilities supported jointly under the TMR Programme for Access to Large-scale Facilities. Beam time at the two facilities is allocated on the basis of a review of research proposals by Programme Advisory Committees with EU membership. Access is free of charge for all non-proprietary research. Limited funding for travel is available for researchers from EU countries.

The deadline for the present call is 1 December 1997.

FELIX at the FOM Institute for Plasma Physics, Nieuwegein, The Netherlands

The FELIX facility provides continuously tunable infrared radiation in the range of 5-110 μm , at peak powers up to 100 MW in sub-ps pulses. Ancillary equipment includes synchronized visible lasers and a 60T pulsed magnet facility. The present call concerns the period March - August 1998.

Information about FELIX and ancillary equipment, including guidelines for submitting a proposal, is available on internet: <http://www.rijnh.nl/DEPARTMENTS/LASER/FELIX/USER/user.html> or via e-mail: lauravv@rijnh.nl.

CLIO at LURE, Orsay, France

The CLIO laser user facility provides a beam in the spectral range: 3 to 53 μm (continuously tunable) with peak power: 10 to 100 MW (in 0.5 to 6 ps pulses, minimum linewidth $\approx 0.3\%$), repetition rate of 32 to 4 ns (during 10 μs macropulses 1-50 Hz) and average power up to 2 W. Laser pulses at 2 different wavelengths can be produced, for ps time resolved 2-color pump-probe experiments. Ancillary equipment (in particular OPOs between 2 to 6 μm) is available.

Those interested in the use of CLIO in 1998 are invited to submit a research proposal on requests forms, which are available from Mrs M. Le Monze, LURE, Bat. 209 D, Université Paris-Sud, 91405 - Orsay, France. Fax: +33-1-6446-4148, Tel.: -8014, e-mail: lemonze@lure.u-psud.fr. More information is available on: <http://www.lure.u-psud.fr>.